Payment overview · 2025
General Payments
$464.09
22 reported records · 5 companies
Healthcare provider profile · identity verified
Khadian Smith
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BLUE BELL, PA · NPI 1629531108
Verified facts
What the public records show
CMS Open Payments records show Khadian Smith received $464.09 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.83 | 42.8% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $134.68 | 29.0% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.35 | 10.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.24 | 9.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $38.99 | 8.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $464.09 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $151.38 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.89 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.03 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.45 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $45.90 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.24 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 392 | 132 |
| Gabapentin | Gabapentin | 268 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 185 | 30 |
| Losartan Potassium | Losartan Potassium | 159 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 143 | 34 |
| Lisinopril | Lisinopril | 135 | 46 |
| Omeprazole | Omeprazole | 133 | 45 |
| Ibuprofen | Ibuprofen | 125 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 29 |
| Metformin Hcl | Metformin Hcl | 111 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 34 |
| Endocet | Oxycodone Hcl/Acetaminophen | 107 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 26 |
| Promethazine Hcl | Promethazine Hcl | 92 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 22 |
| Alprazolam | Alprazolam | 85 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 25 |
| Furosemide | Furosemide | 76 | 27 |
| Glipizide Er | Glipizide | 71 | 20 |
| Nifedipine Er | Nifedipine | 71 | 24 |
| Tramadol Hcl | Tramadol Hcl | 71 | 14 |
| Ozempic | Semaglutide | 68 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 12 |
| Carvedilol | Carvedilol | 64 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 23 |
| Azithromycin | Azithromycin | 59 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 14 |
| Trulicity | Dulaglutide | 58 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 57 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 28 |
| Simvastatin | Simvastatin | 56 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 19 |
| Famotidine | Famotidine | 48 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 18 |
| Montelukast Sodium | Montelukast Sodium | 44 | 14 |
| Jardiance | Empagliflozin | 43 | 13 |
| Levetiracetam | Levetiracetam | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 39 | 11 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Trazodone Hcl | Trazodone Hcl | 36 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | 13 |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Eliquis | Apixaban | 32 | 12 |
| Glipizide | Glipizide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 18 |
| Valsartan | Valsartan | 30 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | 11 |
| Diazepam | Diazepam | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Prednisone | Prednisone | 21 | 12 |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 14 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Stribild | Elviteg/Cob/Emtri/Tenofo Disop | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $464.09 · 22 records | ABBVIE INC. | AIRSUPRA, AUSTEDO XR, BREZTRI, FARXIGA, MOUNJARO, Ozempic, Rybelsus, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error